Dr. Amy Reichelt is a behavioural neuroscientist, psychotherapist, and key opinion leader in obesity, metabolic psychiatry, and the neurobiology of behaviour change. She holds a PhD in Behavioural Neuroscience from Cardiff University and brings more than 15 years of experience spanning academic research, clinical science, medical affairs, and patient-centred care.

‍

‍

Dr. Reichelt’s work focuses on the complex interplay between metabolism, brain function, and mental health, with particular expertise in obesity, food addiction, emotional eating, and the neurobehavioural drivers of weight regulation. Her research and clinical work explore how reward circuitry, stress, trauma, hormonal shifts, inflammation, and ultra-processed food environments shape appetite, cravings, satiety, and long-term health outcomes. She is widely recognized for translating complex neuroscience into practical, clinically meaningful insights for both healthcare professionals and patients.

‍

‍

A leading voice in the emerging field of metabolic psychiatry, Dr. Reichelt has published research on the therapeutic potential of glucagon-like peptide-1 (GLP-1) receptor agonists in psychiatric and neurological disorders, including depression, addiction, cognitive dysfunction, and neurodegenerative disease. Her work highlights the growing recognition that metabolic pathways, including insulin signalling, inflammatory regulation, and gut–brain communication, play a central role in mental health, opening new opportunities for integrated treatment approaches.

‍

‍

In addition to her research expertise, Dr. Reichelt brings deep clinical insight from her work as a psychotherapist supporting individuals with obesity, binge eating, food addiction, body image challenges, and weight-related shame. Her therapeutic approach integrates evidence-based modalities including Acceptance and Commitment Therapy (ACT), somatic and nervous system-informed interventions, and behaviour change science to foster sustainable, compassionate change.

‍

‍

Dr. Reichelt has advised biotechnology, pharmaceutical, and digital health organizations on obesity therapeutics, metabolic health strategy, and patient-centred program development. As a speaker, educator, and advisor, she is known for bridging scientific rigor with empathy, advocating for a more nuanced, stigma-free understanding of obesity as a chronic, multifactorial condition shaped by biology, psychology, environment, and lived experience.